By expressing constitutively active or dominant negative forms of Rho GTPases, and by using specific inhibitors of Rac1, Cdc42, and JNK, we further confirmed the role of impairments in Rho GTPase signaling in mediating metformin effects on the survival of neuroblastoma cells. This evidence concerns the gene CDC42 and neuroblastoma.